Aggressive Lymphomas
From the Journals
PET/CT accurately predicts MCL stage
The promising results suggest bone marrow involvement could be assessed without a biopsy.
News
Treatment improves PFS in early stage FL
A multidrug regimen can improve upon involved-field radiotherapy (IFRT) in patients with early stage follicular lymphoma (FL), according to...
News
Adult CCSs report financial hardships
Health-related financial hardship is common among adult survivors of childhood cancer, according to a study published in the Journal of the...
From the Journals
Isavuconazole resolved invasive fungal disease in patients on ibrutinib
Four of eight patients experienced clinical and radiographic resolution; three improved.
News
Global burden of hematologic malignancies
Research has shown an increase in the global incidence of leukemia and non-Hodgkin lymphoma (NHL) in recent years. The Global Burden of Disease (...
News
Drug receives fast track designation for WM
The US Food and Drug Administration (FDA) has granted fast track designation to zanubrutinib for the treatment of Waldenström’s macroglobulinemia...
News
FDA approves biosimilar filgrastim
The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (...
News
Diabetics have higher risk of hematologic, other cancers
A review of data from more than 19 million people indicates that diabetes significantly raises a person’s risk of developing cancer. When...
News
PET-guided treatment didn’t improve outcomes
In the PETAL trial, treatment intensification based on results of an interim positron emission tomography (PET) scan did not improve survival...
From the Journals
New guideline for managing MCL
Conference Coverage
Ibrutinib/venetoclax shows early promise in relapsed CLL
STOCKHOLM – An ongoing study shows a high clinical response rate and acceptable safety profile with the chemotherapy-free targeted therapy...